Search

CET and skills guides

Study and gain CET points through OT’s online CET exams, and access archived CET, CPD articles and skills guides in our education library

Find out more

Science and vision

News and features about the latest scientific developments and advances in optometry, ophthalmology and eye medicine

Find out more

Industry

News and features about the latest developments in optics with a focus on industry

Find out more

Professional support

News and features about the latest developments relating to professional support from across optics. This includes updates from optical organisations such as the AOP and the GOC

Find out more

In practice

News and in-depth features about business management and career development in optics

Find out more

Jobs

Explore the latest UK and global jobs in the optical sector for optometrists, dispensing opticians and more

Find out more

Bayer to appeal High Court AMD drug ruling

The pharmaceutical company is aiming to uphold patient access to licensed treatment options for wet AMD

Injection

Pharmaceutical company Bayer will appeal against a High Court decision that favoured a policy to offer an unlicensed drug for the treatment of wet age-related macular degeneration (AMD).

The policy to offer bevacizumab, which is marketed as Avastin by Roche, was adopted by 12 clinical commissioning groups in the north of England because of its price difference to other licensed drugs.

In September last year, the High Court ruled against Bayer and Novartis who challenged the lawfulness of the drug’s use for treating wet AMD.

Bayer is appealing the decision in order to uphold patient access to licensed and National Institute for Health and Care Excellence recommended treatments for wet AMD.

In a statement, Bayer said: “Patient need and safety remain Bayer’s highest priority and we are committed to ensuring patients have access to licensed medicines, adhering to regulatory frameworks that are designed to further innovation and protect public health.”

The company added that the appeal will consider whether different means of preparation and supply of bevacizumab for the use in the eye can be lawful.

Novartis is also appealing the High Court decision as it believes that if left unchallenged, the policy will have “profound implications for the regulatory system,” which could put patients at unnecessary risk.

In a statement, Novartis said: “The use of an unlicensed medicine in wet AMD when licensed options are available undermines a patient’s right to medicines that have met stringent regulatory requirements for efficacy, safety and quality and the well-established legal and regulatory framework that is there to protect patients and ensure health professionals can prescribe with confidence.” 

Image credit: Getty